First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in ms

Journal of Neurology

Volumn 261, Issue 1, 2014, Pages 2016-2018

  Malmeström, Clas ^a   Lycke, Jan ^a   Andersson, Bengt A ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; AUTOANTIBODY; MONOCLONAL ANTIBODY;

ADULT; BLOOD; CASE REPORT; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS; FEMALE; GRAVES DISEASE; HUMAN; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; DIABETES MELLITUS; FEMALE; GRAVES DISEASE; HUMANS; MULTIPLE SCLEROSIS;

EID: 84914698618     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7448-y     Document Type: Article

References (9)

1. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, Investigators C-MI (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet 380:1819-1828
2. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, Investigators C-MI (2012) Alemtuzumab for patients with relapsing multiple sclerosis after diseasemodifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829-1839
3. Cossburn M, Pace AA, Jones J, Ali R, Ingram G, Baker K, Hirst C, Zajicek J, Scolding N, Boggild M, Pickersgill T, Ben-Shlomo Y, Coles A, Robertson NP (2011) Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 77:573-579
4. Knip M, Korhonen S, Kulmala P, Veijola R, Reunanen A, Raitakari OT, Viikari J, Akerblom HK (2010) Prediction of type 1 diabetes in the general population. Diabetes Care 33:1206-1212
5. Nokoff N, Rewers M (2013) Pathogenesis of type 1 diabetes: lessons from natural history studies of high-risk individuals. Ann NY Acad Sci 1281:1-15
6. Todd JA (2010) Etiology of type 1 diabetes. Immunity 32:457-467
7. Watkins RA, Evans-Molina C, Blum JS, Dimeglio LA (2014) Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review. Transl Res. doi:10.1016/j.trsl.2014.02.004
8. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton JC (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 104:17040-17045
9. Ziegler AG, Nepom GT (2010) Prediction and pathogenesis in type 1 diabetes. Immunity 32:468-478